Skip to main content
ALGN
NASDAQ Life Sciences

Align Technology's Q1 Revenue, Profit Beat Estimates; FY Guidance Maintained

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$187.6
Mkt Cap
$12.777B
52W Low
$122
52W High
$208.305
Market data snapshot near publication time

summarizeSummary

Align Technology reported strong first-quarter results, with revenue reaching $1.04 billion and adjusted EPS of $2.58, both surpassing analyst consensus estimates of $1.02 billion and $2.28, respectively. This positive performance was driven by higher clear aligner shipments, particularly with double-digit growth in EMEA, APAC, and LATAM. The company also reaffirmed its full-year 2026 revenue growth guidance of 3% to 4% year-over-year, signaling confidence in its outlook despite anticipating some impact from the Middle East conflict on Q2 demand. Additionally, Align completed a $200 million share repurchase program during the quarter. This solid earnings beat and maintained guidance are significant positive catalysts for the stock, indicating robust operational health and stable market demand.

At the time of this announcement, ALGN was trading at $187.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8B. The 52-week trading range was $122.00 to $208.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


show_chartPrice Chart

Share this article

Copied!

feed ALGN - Latest Insights

ALGN
Apr 29, 2026, 4:18 PM EDT
Source: Reuters
Importance Score:
8
ALGN
Feb 27, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
7
ALGN
Feb 04, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8